Vivitrol, Suboxone and methadone: What we know about medicines used to treat opioid addiction. ... Vivitrol is given as an injection that releases naltrexone into the body over about 30 days.

The FDA announced that it has approved Brixadi, an extended-release subcutaneous injection for the treatment of moderate to severe opioid use disorder.Brixadi (buprenorphine, Braeburn Inc.) is the ...

Oral forms of buprenorphine have been available to treat addiction since 2002 and can be purchased as a generic for less than $100 a month.Injectable buprenorphine, sold under the brand name ...

FDA accepts Braeburn’s New Drug Application resubmission for Brixadi ™ (buprenorphine) extended-release subcutaneous injection for moderate to severe opioid use disorder. News release. Braeburn.

SILVER SPRING, Md., Nov. 30, 2017 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Sublocade, the first once-monthly injectable buprenorphine product for the ...

Bicycle Health, a provider of telemedicine treatment for opioid use disorder, announced that it will make prescriptions for buprenorphine extended release injections (known as Sublocade) available ...

If approved, Brixadi would be supplied as weekly (8mg, 16mg, 24mg, 32mg) and monthly (64mg, 96mg, 128mg) injections and would be used as part of a complete treatment plan to include counseling and ...

ALA-1000 is the first, three-month slow-release Buprenorphine injection. Initial results show a low initial burst without dose dumping effect, good safety, and tolerability. ALA-1000 has the ...

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase Ill Trials. Clin Pharmacokinet. 2021;60(4 ...

Opinon/Trapassi: Suboxone not the only answer, ... In 2021, it became the first state to legalize safe injection sites in an effort to reduce the number of opioid overdoses.

SLOUGH, England and RICHMOND, Va., Dec. 2, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) announced today that new analysis from a 12-month investigation of monthly buprenorphine extended-release ...

Sublocade comes as a liquid solution that’s given by subcutaneous injection.It contains the active drug buprenorphine, which belongs to a class of drugs called partial opioid agonists.